Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?

Liquidia (LQDA) generated $170.4M in Q2 Yutrepia net product sales (vs. $6.5M a year earlier) and $74.7M Q2 net income, but Zacks EPS estimates were revised down (2026 EPS to $2.57 from $2.97). Insmed (INSM) received FDA approval for Brinsupri in 2025 and raised full-year 2026 revenue guidance to $1.25–$1.40B from at least $1B; TPIP is in phase III for PH-ILD and PAH with positive 12-month data in an extension study. Despite higher valuation (INSM trades ~10.65x forward sales vs. LQDA ~6.53x) and INSM shares down 28.5% YTD vs. LQDA up 106.9%, the article argues INSM’s more diversified revenue base and deeper pipeline make it the more compelling long-term growth pick.

Analysis

The market is likely underestimating how much of the current relative performance is a de-risking story versus a durable re-rating. For INSM, a second commercial asset plus cash generation creates internal funding for TPIP and the rest of the pipeline, which lowers dilution risk and supports a higher terminal multiple if launch execution stays intact. For LQDA, the near-term upside is more fragile: a single-product story can screen optically cheap on sales, but that discount is warranted if payer friction or a competing inhaled platform slows the slope of new starts.

The key competitive dynamic is not just share theft between Yutrepia and TPIP; it is whether inhaled prostacyclin expands as a class or gets commoditized by the first differentiated device that wins prescriber habit. If the class expands, both names can work, but the later-stage entrant with broader cash flow still deserves the premium because it can tolerate a slower uptake curve. If the class commoditizes, LQDA’s growth rate should normalize faster than the market expects, and the estimate cuts are an early warning that sell-side models may still be too high.

Time horizon matters: over the next 1-3 months the tape should react to prescription momentum and any guidance revision, while the 6-18 month driver is TPIP read-through and whether Brinsupri sustains a multi-quarter launch trajectory. The contrarian view is that INSM’s premium valuation is less a mistake than an option on pipeline breadth, whereas LQDA’s lower multiple may simply be compensating for concentration risk. What would falsify the bullish INSM view is a Brinsupri plateau or reimbursement drag; what would falsify the bearish LQDA setup is continued acceleration in starts without meaningful payer pushback.

Key Decisions for Investors

• Preferred expression: long INSM / short LQDA as a quality-vs-concentration pair trade over the next 1-3 quarters; thesis wins if INSM keeps raising launch guidance while LQDA’s growth decelerates. Risk: if inhaled PH expands faster than expected, both legs can work and the spread may not widen sharply.
• Add INSM on post-volatility weakness rather than chasing strength; the best entry is after any pullback tied to broader biotech risk-off, with a 6-12 month target on continued revenue re-rating and lower dilution probability.
• Avoid initiating fresh LQDA longs until the next prescription or reimbursement data point confirms that early conversion is scaling beyond the initial launch cohort. The stock can stay momentum-driven, but the setup is vulnerable to any deceleration in new starts or downward estimate revisions.
• For event-driven accounts, buy INSM call spreads into the next quarterly update to express upside from another guidance raise while limiting premium burn; the catalyst path is clearer than for LQDA because Brinsupri has a bigger financial base behind it.
• Watch TPIP clinical timing as the main optionality catalyst for both names; if phase III readouts or enrollment updates slip, the market should compress the entire inhaled prostacyclin complex, with LQDA more exposed because it lacks diversification.